Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Domain Therapeutics appoints chair of board

This article was originally published in Scrip

Executive Summary

Strasbourg, France-based Domain Therapeutics, a biopharmaceutical company specializing in the development of new drug candidates targeting G protein-coupled receptors (GPCRs), has named Dr Youssef L Bennani chair of its board of directors. Dr Bennani is currently site head and vice-president of R&D at Vertex Pharmaceuticals' site in Laval, Quebec. He replaces Sam Eletr who held the position of chair of the board from November 2008 to April 2014. Mr Eletr remains a contributing shareholder of Domain.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts